Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Metastatic Pancreatic Ductal Adenocarcinoma
NCT02558894Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2015
- Primary completion
- Jun 2017
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 6
01
Overview
A Phase 2 trial of durvalumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by AstraZeneca. Started Nov 2015; status: completed.
02
Drugs
durvalumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02558894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02558894.